Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicentre, Open-label Study to Evaluate the Pharmacokinetic, Safety and Preliminary Efficacy of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Subjects With Severe Hemophilia A

Next Previous
Trial Profile

A Phase II, Multicentre, Open-label Study to Evaluate the Pharmacokinetic, Safety and Preliminary Efficacy of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Subjects With Severe Hemophilia A

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FRSW 117 (Primary)
  • Indications Haemophilia A
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Jiangsu Gensciences

Most Recent Events

  • 12 Dec 2023 Results evalueting PK, safety, and preliminary efficacy of multiple 4 doses of FRSW117 in previously treated subjects with severe Hemophilia A ,presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 12 May 2023 Status changed from recruiting to completed.
  • 27 Jun 2022 Planned End Date changed from 30 Nov 2022 to 31 Jul 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top